Company Overview of Synthetic Genomics, Inc.
Synthetic Genomics, Inc. develops synthetic DNA solutions to organizations with demands for large and/or complex DNA constructs. It engages in designing metabolic pathways for the production of biochemicals and next generation biofuels from various feedstocks; developing biological solutions to increase the conversion and recovery rates of subsurface hydrocarbons; and developing advanced plant feedstocks and microbial agents for agriculture. Synthetic Genomics, Inc. was formerly known as Synthetic Genomic Solutions, Inc. The company was founded in 2005 and is based in La Jolla, California.
11149 North Torrey Pines Road
La Jolla, CA 92037
Founded in 2005
Key Executives for Synthetic Genomics, Inc.
Co-Founder and Co-Chief Scientific Officer
Compensation as of Fiscal Year 2014.
Synthetic Genomics, Inc. Key Developments
Avoca, Inc. Signs Supply Agreement with Synthetic Genomics, Inc. to Become Domestic Source of Natural Astaxanthin
Jun 20 14
Avoca, Inc. has formed a supply agreement with Synthetic Genomics, Inc. to extract and commercialize natural astaxanthin from a strain of algae developed by SGI. The multi-year supply agreement also provides Avoca with exclusivity for product sales in North America. Pharmachem Laboratories will be responsible for marketing and sales. SGI is developing this product through their Genovia Bio business unit, which is responsible for the development and commercialization of algal-based food, chemical and fuel products. Financial details were not disclosed. Natural astaxanthin is a supplement with multiple clinically-proven health benefits associated with its powerful antioxidant and anti-inflammatory properties. Natural astaxanthin is very difficult to produce and therefore supply constrained relative to demand. SGI has developed a process for production of natural astaxanthin from a phototrophic source and demonstrated commercial-scale manufacturing capability and performance over 18 months. SGI's natural astaxanthin has U.S. Food and Drug Administration regulatory approval for dietary supplement applications.
Synthetic Genomics Inc. Signs Collaborative Research and Development Agreement with Lung Biotechnology Inc. to Develop Humanized Pig Organs to Revolutionize Transplantation Field
May 6 14
Synthetic Genomics Inc. and Lung Biotechnology Inc. announced they have entered into a multi-year research and development agreement to develop humanized pig organs using synthetic genomic advances. The collaboration will focus upon developing organs for human patients in need of transplantation, with an initial focus on lung diseases. As part of the agreement SGI will receive royalties and milestone incentives from the development and commercialization of the organs. Using unique DNA design, DNA synthesis and genome editing, as well as genome modification tools, SGI will develop engineered primary pig cells with modified genomes. This work will entail modification of a substantial number of genes at an unprecedented scale and efficiency. United Therapeutics will leverage its xenotransplantation expertise to implant these engineered cells, generating pig embryos which develop and are born with humanized lungs. With the science and technology advances made by the SGI team in recent years, the companies are striving to develop these new methods and advances to create organs that are safe and effective for use in humans.
Synthetic Genomics, Inc. Presents at 2013 Pacific Rim Summit on Industrial Biotechnology and Bioenergy, Dec-08-2013 through Dec-11-2013
Dec 5 13
Synthetic Genomics, Inc. Presents at 2013 Pacific Rim Summit on Industrial Biotechnology and Bioenergy, Dec-08-2013 through Dec-11-2013. Venue: Westin Gaslamp Quarter, San Diego, California, United States. Presentation Date & Speakers: Dec-09-2013, James Flatt, Chief Technology Officer. Dec-10-2013, J. Craig Venter, Co-Founder, Chairman, Chief Executive Officer and Co-Chief Scientific Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 6, 2014